Oregon Osteoporosis Center
Endocrinology
Dr. Michael C. McClung, DC
|
|
Give Review
Michael McClung works in the field of Endocrinology. He went to University of Texas Southwestern Medical School. He has 2 awards "Portland Monthly Magazine" and "Fellow (FACP)". Michael C. McClung, DC is a published physician as well. He has 58 publications published. The latest was: Vertebral fractures: clinical importance and management. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacat...
- New management options for osteoporosis with emphasis on SERMs.
- Vertebral fractures: clinical importance and management.
- Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing.
- Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture ...
- Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
- Creation of an Age-Adjusted, Dual-Energy X-ray Absorptiometry-Derived Trabecular Bone Score Curve for the Lumbar Spine in Non-Hispanic US White Women.
- Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density.
- Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
- Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis.
- Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study.
- Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
- Osteoporosis Update From the 2012 Santa Fe Bone Symposium.
- Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
- Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
- In memoriam: sergio ragi-eis, MD.
- Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
- A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data.
- Revisiting the prevention of bone loss at menopause.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
- Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
- A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density.
- To FRAX or not to FRAX.
- Femoral strength in osteoporotic women treated with teriparatide or alendronate.
- Effects of denosumab on fracture and bone mineral density by level of kidney function.
- Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
- Osteoporosis update from the 2010 santa fe bone symposium.
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive su...
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
- Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.
- Postmenopausal osteoporosis: fracture risk and prevention.
- Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
- Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
- Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
- Looking for answers in all the wrong places.
- Bisphosphonates and osteonecrosis of the jaw.
- Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following Discontinuation.
- Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
- Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
- Do current management strategies and guidelines adequately address fracture risk?
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
- Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
- Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
- The relationship between bone mineral density and fracture risk.
- Osteopenia: to treat or not to treat?
- Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and ...
- Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.
- Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.
- Bisphosphonates.
- Pathogenesis of osteoporotic hip fractures.
- How does raloxifene reduce fracture risk?
- Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
- Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial.
- A national random survey of bone mineral density reporting in the United States.
Schools
Texas Chiropractic College
University of Texas Austin Campus
Licensed Neuropathy Clinic Of Neuropathydr With Ongoing Training
San Diego Spine Institute
Procedures Preformed
- Cold Laser Therapy
- Electrophysiology
- Manipulation Adjustment of Back and Neck
- Minimally Invasive Decompression for Spinal Stenosis
- View All
Conditions Treated
- Carpal Tunnel Syndrome
- Chronic Pain
- Intervertebral Disc Herniation
- Neuropathy, Motor and Sensory
- View All
Doctors Specialties
- Chiropractic
- Endocrinology
Accepted Insurances
Awards
- Portland Monthly Magazine
- Fellow (FACP)
Education
-
University of Texas Southwestern Medical School
Hospital
-
Providence Portland Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245313451 |
| Last Name Of The Provider | MCCLUNG |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. Simona M. Scumpia, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Kavita Juneja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michele T. McDermott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan K. Dubois, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis Casaubon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven H. Fehrenkamp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maya B. Bledsoe, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Venkatesh B. Segu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael K. Turner, DC |
|
|
Dr. Shea Oharrow, DC |
|
Dr. Melanie M. Spindler, MD |